The US Food and Drug Administration (FDA) has approved Abbott’s Portico with FlexNav transcatheter aortic valve replacement (TAVR) system to treat individuals with symptomatic, severe aortic stenosis.
The system is intended for use in patients who are at high or extreme risk for open-heart surgery.
A self-expanding TAVR valve with intra-annular leaflets within the native valve, Portico could aid in providing streamlined blood flow or haemodynamics when placed inside a patient’s natural valve.
